0.55Open0.55Pre Close0 Volume275 Open Interest320.00Strike Price0.00Turnover52.98%IV30.90%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type0.0403Delta0.0024Gamma445.25Leverage Ratio-0.0560Theta0.0070Rho17.94Eff Leverage0.0582Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet